Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T; Kyushu Taxol TS-1 Study Group. Nakajo A, et al. Among authors: hamanoue m. Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9. doi: 10.1007/s00280-008-0693-y. Epub 2008 Mar 4. Cancer Chemother Pharmacol. 2008. PMID: 18317763 Clinical Trial.
Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D, Uenosono Y, Arigami T, Yanagita S, Okubo K, Kijima T, Miyazono F, Hamanoue M, Hokita S, Nakashima S, Ohtsuka T, Natsugoe S. Matsushita D, et al. Among authors: hamanoue m. Cancer Chemother Pharmacol. 2021 Jun;87(6):789-797. doi: 10.1007/s00280-021-04251-z. Epub 2021 Feb 28. Cancer Chemother Pharmacol. 2021. PMID: 33641065
A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.
Aridome K, Mori SI, Baba K, Yanagi M, Hamanoue M, Miyazono F, Tokuda K, Imamura H, Ogura Y, Kaneko K, Kijima F, Maemura K, Ishigami S, Natsugoe S. Aridome K, et al. Among authors: hamanoue m. Mol Clin Oncol. 2016 Mar;4(3):393-398. doi: 10.3892/mco.2015.724. Epub 2015 Dec 31. Mol Clin Oncol. 2016. PMID: 26998290 Free PMC article.
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H, Shimose T, Shimokawa M, Saeki H, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Ando K, et al. Among authors: hamanoue m. Int J Clin Oncol. 2017 Oct;22(5):913-920. doi: 10.1007/s10147-017-1140-z. Epub 2017 May 19. Int J Clin Oncol. 2017. PMID: 28526907 Clinical Trial.
63 results